Public largely supportive of big genetic studies

By Anthony J. Brown, MD

NEW YORK (Reuters Health) - A survey of over 4,500 Americans reveals that most are in favor of large studies examining how genes, the environment, and lifestyle interact to affect the risk of a given disease.

The survey results, which were presented Wednesday at the American Society of Human Genetics annual meeting in Philadelphia, also indicate that most subjects were willing to participate in such studies. Moreover, this willingness remained high, regardless of ethnic background, race or other demographic factors.

“We had two big findings,” lead author Dr. David Kaufman told Reuters Health. “First, we saw that support for the…study and willingness to participate were consistent across all demographic groups including race and ethnic groups. This was a surprise, particularly since several studies have shown lower interest and participation in genetic research among African Americans and other minorities.”

The other big finding related to incentives for study participation. “We found that giving study participants their individual research results related to health had a stronger influence on willingness to participate than compensation they would receive or how burdensome study participation would be,” Kaufman, a researcher with John Hopkins University, Baltimore, said.

According to the report, 84 percent of respondents said that large genetic studies should definitely or probably be done. Sixty percent said that they would probably or definitely be willing to participate in such studies if offered the chance.

Providing the research results to participants and providing financial compensation increased the likelihood of participation by 60 percent and 50 percent, respectively. Making participation in the study easier, by contrast, only increased the odds by 20 percent.

Consistent with the other findings, 75 percent of subjects said that their willingness to participate would fall if not given the research results. Moreover, 91 percent of respondents wanted their results even if they were of no immediate value.

“The larger point is that people are hungry for information about themselves and their health,” Kaufman said. “If something is learned about them during a research study, they want to have the option to find out about it.”

Regarding future research, he said that his team is “interested in finding out whether passage of the Genetic Information Nondiscrimination Act (GINA) changed people’s attitudes about (large cohort genetic studies), since this work was conducted before the legislation was signed.”

GINA, which was passed in May this year, is designed to protect Americans from discrimination based on their genetic information in the areas of health insurance and employment.


Related Posts:

By Megan Rauscher NEW YORK (Reuters Health) - Among United States Latinas, a greater degree of European genetic ancestry is associated with an increased risk of breast cancer, the results of a new study indicate. This could be due to environmental factors, genetic factors, or the interplay of the two, the study team suggests. Latina women generally

Full Post: European origin may up Latinas’ breast cancer risk

By Megan Rauscher NEW YORK (Reuters Health) - Older adults who regularly take part in top-rated, low-cost physical activity programs offered by their local senior center or YMCA can see noticeable improvement in physical functioning and lower their risk of becoming disabled, research shows. “Older adults can benefit greatly from these programs,” Susan L. Hughes told Reuters

Full Post: The best exercise programs benefit the elderly

By Joene Hendry NEW YORK (Reuters Health) - Use of a non-steroidal anti-inflammatory drug (NSAID) for over 5 years may lessen a person’s risk of developing cancer of the lower portion of the large bowel, study findings suggest. This risk reduction appears more robust among whites than among African Americans, Dr. Sangmi Kim, of the National Institute

Full Post: Pain pills may cut risk of bowel cancer: study

By Susan Heavey WASHINGTON (Reuters) - U.S. health regulators are questioning whether clinical trials proposed by ImClone Systems and Amgen Inc will be adequate to show that patients with a certain type of gene are more likely to be helped by two cancer drugs, according to documents released on Friday. Early research has indicated that patients with

Full Post: FDA questions Lilly, Amgen cancer drug trials

By Michael Kahn LONDON (Reuters) - Many genes linked to various cancers do not appear to raise the risk of getting cancer after all, according to an analysis of hundreds of studies published on Tuesday. The findings highlight the need to exercise caution over the increasing number of studies associating common genetic variations with a range of

Full Post: Many studies needed to tie genes to cancer: study

Site Navigation

Most Read